TAKESHI MASUDA

Last Updated :2020/08/03

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
ta-masudahiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2013/04/01, 2014/03/31, Hiroshima University Hospital, Clinical Fellow
  • 2014/04/01, Hiroshima University Hospital, Assistant Professor

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;General internal medicine (including psychosomatic medicine)

Research Keywords

  • Respiratory Internal Medicine
  • Clinical Oncology
  • Lung cancer

Educational Activity

Course in Charge

  1. 2020, Undergraduate Education, Intensive, Symptomatology, Diagnosis and Treatment
  2. 2020, Undergraduate Education, Intensive, Introduction to clinical clerkship

Research Activities

Academic Papers

  1. Coexisting TIF1ganma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1ganma Antibody-positive Dermatomyositis: A Case Report, Intern Med .
  2. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Respir Res .
  3. SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis, MOLECULAR CANCER THERAPEUTICS, 12(11), 2378-2388, 201311
  4. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model, CANCER SCIENCE, 106(7), 921-928, 201507
  5. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung, PHARMACEUTICAL RESEARCH, 32(12), 3877-3885, 201512
  6. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts, PLOS ONE, 11(2), 20160209
  7. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy., Cancer chemotherapy and pharmacology, 67(6), 1465-1469, 2011
  8. A retrospective study comparing pemetrexed with taxanes as front-line cytotoxic chemotherapy for lung adenocarcinoma, ANNALS OF ONCOLOGY, 26, 123-123, 2015
  9. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 20160517
  10. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma, CANCER RESEARCH, 76(11), 3285-3294, 20160601
  11. Two Cases of Lung Cancer with Carcinomatous Meningitis in Which Erlotinib Was Effective After Gefitinib Therapy, 49, 203-213, 2009
  12. A Case of Malignant Pleural Mesothelioma Appearing as a Solitary Mass, Japanese Journal of Lung Cancer, 48(7), 825-831, 2008
  13. Acase of delayed onset pleural tuberculoma during the treatment for tuberculous pleurisy, 34(10), 1014-1015, 2015
  14. Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals, FREE RADICAL BIOLOGY AND MEDICINE, 106, 1-9, 201705
  15. A Case of Central Diabetes Insipidus That Was Caused by Pituitary Metastasis of Lung Adenocarcinoma and Was Controlled by Radiation Therapy, Gan To Kagaku Ryoho, 44(6), 513-516, 201706
  16. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 201710
  17. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis., Internal Medicine, 11, 201712
  18. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer., Cancer Chemother Pharmacology, 201711
  19. Terminating Chemotherapy and Transition to Palliative Care for Patients with Recurrent Non-small Cell Lung Cancer in the Terminal Stage, Japanese Journal of Lung Cancer, 49(6), 836-843, 200910
  20. Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma., Eur Respir J, 20180308
  21. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, Oncotarget, 55(8), 94382-94392, 20171010
  22. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma., Lung Cancer, 119, 21-24, 2018
  23. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 201800
  24. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, 20180907
  25. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, 201810
  26. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1., Cancer Letter, 30(442), 31-39, 201810
  27. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study., Mol Clin Oncol., 9(5), 539-534, 201811
  28. Performance status is a risk factor for depression before diagnosis in patients with lung cancer, Internal Medicine, 915-920, 2019, 4
  29. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: a retrospective cohort study, Medicine, 97(49), e13542, 2018, 12
  30. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study, BMC cancer, 18(1), 1231, 2018, 12, 10
  31. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, Journal of Cellular and Molecular Medicine, 23(4), 2984-2994, 2019, April
  32. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), e14296, 201902
  33. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), e14821, 2019 Mar
  34. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress., Free Radic Biol Med, 136, 52-59, 2019, May, 20
  35. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, respirology
  36. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, Respiratory Investigation
  37. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, Internal Medicine
  38. C-C motif chemokine ligand 15 may be a useful biomarker for predicting the prognosis of patients with chronic hypersensitivity pneumonitis, Respiration
  39. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  40. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy., Invest New Drugs., 2019. 8
  41. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY), CHEST, 156(2), 357-366, 201908
  42. 当院におけるEGFR遺伝子変異陽性の既治療非小細胞肺癌に対する再生検の現状, 71, 227-231, 2018
  43. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  44. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer., Int J Clin Oncol, 2019
  45. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC., J Thorac Oncol, 2019, 8
  46. Pulmonary arteriovenous malformation exhibiting recanalization more than ten years after coil embolization: Two case reports, Medicine
  47. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer Running title: PEMBROLIZUMAB FOR ELDERLY PATIENTS WITH NSCLC, Journal of thoracic disease
  48. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan., Lung cancer, 8-18, 2020, 2
  49. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: Subanalysis of a real-world retrospective observational study (CA209-9CR), ESMO Open

Invited Lecture, Oral Presentation, Poster Presentation

  1. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation
  2. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, American Thoracic Society International Conference, San Diego, USA, 2014., 2014, Without Invitation
  3. Gene expression profiles of idiopathic interstitial pneumonitis: Molecular signatures of pulmonary fibrosis, Nobuhisa Ishikawa, Takeshi Masuda, Yasushi Horimasu, Noboru Hattori, Shinichiro Ohshimo, Nobuoki Kohno, 2014, Without Invitation
  4. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis., Takeshi Masuda, Noboru Hattori, Tadashi Senoo, 2014, Without Invitation
  5. SK-216, an inhibitor of plasminogen activator inhibitor-1, inhibits tumor growth in a mouse model of pleural mesothelioma., Yusuke Takayama, Noboru Hattori, Hironobu Hamada, Takeshi Masuda, 2014, Without Invitation
  6. Anti-tumor Effect of MT95-4, a Fully Humanized Anti-Aminopeptidase N Monoclonal Antibody, on Tumor Progression in an Animal Model of Malignant Pleural Mesothelioma., Takahiko Otsuki, Noboru Hattori, Hironobu Hamada, Horimasu Yasushi, Takeshi Masuda, Taku Nakashima, Iwamoto Hiroshi, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/51, Without Invitation
  7. PAI-1 plays an important role in radiatiopn-induced pulmonary fibrosis, Sachiko Shioya, Noboru Hattori, Takeshi Masuda, Tadashi Senoo, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Nobuoki Kohno, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation
  8. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Takeshi Masuda, Noboru Hattori, Yasushi Horimasu, Kazunori Fujitaka, Hironobu Hamada, American Thoracic Society International Conference 2016, 2016/05/13, Without Invitation
  9. Airway reversibility assessed by oscillometry in patients with asthma, Higaki N, Iwamoto H, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fjitaka K, Hamada H, Hattori N, ERS Milan 2017 International Congress, 2017/99, Without Invitation, European Respiratory Society, Milan, Italy
  10. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, T. Masuda. T. Nakashima , M. Namba , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hatttori, American Thoracic Society 2018 International Conference", 2018/51, Without Invitation
  11. Vascular Endothelial Growth Factor Knockdown by Intratracheal Administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth in a Mouse Lung Metastasis Model, K. Miyata. Y. Horimasu , T. Masuda , S. Miyamoto , T. Nakashima , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/51, Without Invitation, Sandiego, USA
  12. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis Are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis, M. Namba. T. Masuda , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , T. Nakashima , H. Iwamoto , S. Ohshimo , K. Fujitaka , H. Hamada , N. Hattori, American Thoracic Society 2018 International Conference, 2018/51, Without Invitation, Sandiego, USA
  13. IPFの遺伝子素因 MUC5B遺伝子多型を中心に, 堀益 靖, 山口 覚博, 坂本 信二郎, 益田 武, 中島 拓, 岩本 博志, 藤高 一慶, 服部 登, 第58回日本呼吸器学会学術講演会, 2018/42, Without Invitation
  14. Pleuroparenchymal fibroelastosisと特発性肺線維症の臨床的相違点の検討, 難波将史,益田武,山口覚博,堀益靖,宮本真太郎,中島拓,岩本博志,藤高一慶,濱田泰伸,服部登, 2018/41, Without Invitation

Awards

  1. 2019, Interstitial Lung Disease Assembly Education Awardee, APSR, Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI, 2018, 2020
  2. KAKENHI, 2015, 2017
  3. 2018, 2019
  4. 2015, 2016

Social Activities

History as Peer Reviews of Academic Papers

  1. 2018, Journal of thoracic disease
  2. 2019, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
  3. 2018, Japanese Journal of Clinical Oncology
  4. 2020, Histology and Histopathology
  5. 2020, Respiratory Investigation
  6. 2019, BMC Research Notes
  7. 2019, Journal of Thoracic Disease
  8. 2016, Oncotarget
  9. 2018, 気管支学
  10. 2018, Scientific Reports
  11. 2019, OncoTargets and Therapy
  12. 2019, Evidence-Based Complementary and Alternative Medicine
  13. 2013, Cancer Science
  14. 2014, Respiratory Investigation
  15. 2014, Internal Medicine
  16. 2014, Japanese Journal of Clinical Oncology
  17. 2014, Annals of Oncology
  18. 2014, Annals of Oncology
  19. 2015, PLOS ONE
  20. 2016, Oncotarget
  21. 2016, Internal medicine